April 28, 2017
Charley’s Fund, Duchenne UK, and Joining Jack join forces on grant to investigate new approach to treat DMD
One of our core values is LEVERAGE. So we are very excited to join forces with partners across the Pond to fund a new research…
August 22, 2016
Summit Keeps Climbing
It's taking a long time, but it's happening! Summit Therapeutics, a UK-based company we began supporting nine years ago, is making significant progress on its experimental…
June 22, 2016
Update on the HT-100 program
Earlier this week at the annual PPMD Connect Conference in Orlando, Akashi Therapeutics CMO Dr. Diana Escolar presented an update on the HT-100 program. "We…
May 22, 2016
We remain active on other medical research fronts
While we aggressively advocate for the approval of eteplirsen, we remain active on other medical research fronts. It's important to remember that eteplirsen helps 13%…
April 12, 2016
Meet the Impact Initiative
You probably already know that Charley's Fund is supporting the development of several new medicines to slow or halt Duchenne's deadly progression. Our goal is…